Product: Abraxane® paclitaxel protein-bound particles for injectable


Disease: MBC

Indication: Treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Classic Chemotherapy

Product: Gemcitabine

Disease: Solid tumors

Indication: Indicated for:  Ovarian Cancer in combination with carboplatin  Breast Cancer in combination with paclitaxel  Non-Small Cell Lung Cancer in combination with cisplatin Pancreatic Cancer as a single-agent

Product: Paclitaxel

Disease: Solid tumors

Indication: Treatment of non-small cell lung cancer in patients unsuitable for curative treatment, and in first-line and second-line treatment of ovarian cancer; advanced breast cancer after the failure of anthracyclic chemotherapy and adjuvant treatment of early node-positive breast cancer

Product: Docetaxel

Disease: Solid tumors

Indication: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction. Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN

Product: Oxaliplatin

Disease: Solid tumors

Indication: Indicated in combination with infusional 5fluorouracil /leucovorin, for:  Adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.  Treatment of advanced colorectal cancer

Product: Irinotecan

Disease: Solid tumors

Indication: Indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. Also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

Supportive Care

Product: Kepivance® Palifermin

Disease: Oral Mucositis

Indication: Indicated to decrease the frequency, duration and severity of oral mucositis in adults who are likely to develop severe mucositis because they have blood cancer, and are being treated with myeloablative chemotherapy in combination with radiotherapy and an autologous haematopoietic stem-cell transplant

Product: Emend ® aprepitant

Disease: Anti Emetic

Indication: Emend is an anti-emetic used with other medicines to prevent nausea and vomiting caused by chemotherapy